Créditos: Comité científico CovidLeer más
Hospitalizations and emergency department visits for rebounding COVID-19 symptoms are rare after treatment with the antiviral therapy nirmatrelvir-ritonavir, according to a CDC analysis of electronic medical records from a large health care system.
In late December 2021, the US Food and Drug Administration issued an Emergency Use Authorization for nirmatrelvir-ritonavir (Paxlovid) to treat individuals with COVID-19 at increased risk of severe outcomes including hospitalization and death. Case reports of rebounding COVID-19 symptoms or positive SARS-CoV-2 test results between 2 and 8 days after treatment with the antiviral therapy prompted the CDC to issue a Health Advisory on May 24.
Less than 1% of 5287 patients who received nirmatrelvir-ritonavir for COVID-19 required hospitalization or emergency department care for symptoms 5 to 15 days after treatment, according to the CDC report. Six hospitalizations—all among people with comorbidities or advanced age—and 39 emergency department encounters for apparent COVID-19 symptoms occurred. Two of the hospitalized patients died.
“When administered as an early-stage treatment, Paxlovid might prevent COVID-19–related hospitalization among persons with mild to moderate COVID-19 who are at risk for progression to severe disease,” the report’s authors wrote.
Créditos: Comité científico Covid